Harnessing mega-analysis in the era of "big data" neuroimaging

Luke J Norman^{1

2}, Philip Shaw^{3

4

5}

Affiliations

¹ Office of the Clinical Director, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. luke.norman@nih.gov.
² Section on Neurobehavioral and Clinical Research, Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. luke.norman@nih.gov.
³ Office of the Clinical Director, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
⁴ Section on Neurobehavioral and Clinical Research, Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
⁵ Kings Maudsley Partnership for Children and Young People, Pears Maudsley Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Luke J Norman et al. Neuropsychopharmacology. 2024 Nov.

. 2024 Nov;50(1):332-334.

doi: 10.1038/s41386-024-01964-6.

Luke J Norman^{1

2}, Philip Shaw^{3

4

5}

¹ Office of the Clinical Director, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. luke.norman@nih.gov.
² Section on Neurobehavioral and Clinical Research, Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. luke.norman@nih.gov.
³ Office of the Clinical Director, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
⁴ Section on Neurobehavioral and Clinical Research, Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
⁵ Kings Maudsley Partnership for Children and Young People, Pears Maudsley Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Erratum in

Correction: Neuropsychopharmacology Volume 50 Issue 1.
[No authors listed] [No authors listed] Neuropsychopharmacology. 2025 May;50(6):1019-1020. doi: 10.1038/s41386-025-02087-2. Neuropsychopharmacology. 2025. PMID: 40108440 Free PMC article. No abstract available.

No abstract available

The authors declare no competing interests.

1. Norman LJ, Sudre G, Price J, Shastri GG, Shaw P. Evidence from “big data” for the default-mode hypothesis of ADHD: a mega-analysis of multiple large samples. Neuropsychopharmacology. 2023;48:281–89. - PMC - PubMed
1. Norman LJ, Sudre G, Price J, Shaw P. Subcortico-cortical dysconnectivity in ADHD: a voxel-wise mega-analysis across multiple cohorts. Am J Psychiatry. 2024;181:553–62. - PMC - PubMed
1. Hoogman M, Van Rooij D, Klein M, Boedhoe P, Ilioska I, Li T, et al. Consortium neuroscience of attention deficit/hyperactivity disorder and autism spectrum disorder: the ENIGMA adventure. Hum Brain Mapp. 2020;43:37–55. - PMC - PubMed
1. Sudre G, Norman L, Bouyssi-Kobar M, Price J, Shastri GG, Shaw P. A mega-analytic study of white matter microstructural differences across 5 cohorts of youths with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2023;94:18–28. - PMC - PubMed
1. Mooney MA, Hermosillo RJ, Feczko E, Miranda-Dominguez O, Moore LA, Perrone A, et al. Cumulative effects of resting-state connectivity across all brain networks significantly correlate with ADHD symptoms. J Neurosci. 2024;44:e1202232023. - PMC - PubMed